{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:36:05Z","timestamp":1785551765485,"version":"3.56.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,15]]},"DOI":"10.2146\/ajhp120543","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T11:33:50Z","timestamp":1372764830000},"page":"1230-1237","source":"Crossref","is-referenced-by-count":8,"title":["Relative bioavailability of tolvaptan administered via nasogastric tube and tolvaptan tablets swallowed intact"],"prefix":"10.1093","volume":"70","author":[{"given":"Elizabeth B.","family":"McNeely","sequence":"first","affiliation":[{"name":"Rex Hospital, Raleigh, NC; at the time of writing, she was Heart Failure Pharmacotherapy Fellow, Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill (UNC), Chapel Hill."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine A.","family":"Talameh","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy, College of Medicine, The Ohio State University, Columbus; at the time of writing, she was a Ph.D. candidate, Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Kirkwood F.","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, School of Medicine, UNC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Heyward","family":"Hull","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Simmons","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Henry","sequence":"additional","affiliation":[{"name":"Pharmaceutical Product Development, Inc., Morrisville, NC; at the time of writing, she was Clinical Research\/Drug Development Fellow, Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim L. R.","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Herbert","family":"Patterson","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041206551167200_b1-0701230","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: a new target for the treatment of heart failure","volume":"146","author":"Lee","year":"2003","journal-title":"Am Heart J"},{"key":"2019041206551167200_b2-0701230","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1053\/j.ajkd.2006.01.020","article-title":"Vasopressin excess and hyponatremia","volume":"47","author":"Pham","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2019041206551167200_b3-0701230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","article-title":"Tolvaptan, an orally active vasopressin V(2)-receptor antagonist\u2014pharmacology and clinical trials","volume":"25","author":"Miyazaki","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"2019041206551167200_b4-0701230","first-page":"977","article-title":"Tolvaptan (Otsuka)","volume":"5","author":"Doggrell","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"2019041206551167200_b5-0701230","volume-title":"New drug application for tolvaptan, Otsuka\u2019s investigational novel oral treatment for worsening heart failure and hyponatremia, accepted by the U.S. Food and Drug Administration","year":"2007"},{"key":"2019041206551167200_b6-0701230","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1210\/jcem.82.4.3900","article-title":"Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)","volume":"82","author":"Saito","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041206551167200_b7-0701230","doi-asserted-by":"crossref","first-page":"19L","DOI":"10.1016\/j.amjcard.2005.09.066","article-title":"Hyponatremia in patients with heart failure","volume":"96","author":"De Luca","year":"2005","journal-title":"Am J Cardiol"},{"key":"2019041206551167200_b8-0701230","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1527-5299.2005.04180.x","article-title":"Hyponatremia and heart failure \u2014pathophysiology and implications","volume":"11","author":"Sica","year":"2005","journal-title":"Congest Heart Fail"},{"key":"2019041206551167200_b9-0701230","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"2019041206551167200_b10-0701230","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5414\/CNP65028","article-title":"Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis","volume":"65","author":"Wu","year":"2006","journal-title":"Clin Nephrol"},{"key":"2019041206551167200_b11-0701230","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/gast.2003.50143","article-title":"Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial","volume":"124","author":"Gerbes","year":"2003","journal-title":"Gastroenterology"},{"key":"2019041206551167200_b12-0701230","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","article-title":"Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia","volume":"97","author":"Gheorghiade","year":"2006","journal-title":"Am J Cardiol"},{"key":"2019041206551167200_b13-0701230","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"2019041206551167200_b14-0701230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-7547-4-10","article-title":"Cost of illness of hyponatremia in the United States","volume":"4","author":"Boscoe","year":"2006","journal-title":"Cost Eff Resour Alloc"},{"key":"2019041206551167200_b15-0701230","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S1357-2725(03)00139-0","article-title":"The syndrome of inappropriate antidiuretic hormone secretion","volume":"35","author":"Baylis","year":"2003","journal-title":"Int J Biochem Cell Biol"},{"issue":"suppl","key":"2019041206551167200_b16-0701230","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/j.amjcard.2005.03.004","article-title":"Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure","volume":"95","author":"Goldsmith","year":"2005","journal-title":"Am J Cardiol"},{"key":"2019041206551167200_b17-0701230","author":"Samsca (tolvaptan) package insert","year":"2013"},{"key":"2019041206551167200_b18-0701230","volume-title":"Vaprisol (conivaptan) package insert","year":"2008"},{"key":"2019041206551167200_b19-0701230","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5414\/CP201621","article-title":"Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects","volume":"50","author":"Shoaf","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2019041206551167200_b20-0701230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/2160763X12439702","article-title":"Pharmacokinetic and pharmacodynamic interaction between tolvaptan and warfarin in healthy subjects","volume":"1","author":"Shoaf","year":"2012","journal-title":"Clin Pharm Drug Dev"},{"key":"2019041206551167200_b21-0701230","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","article-title":"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a nonpeptide AVP antagonist in healthy subjects","volume":"73","author":"Shoaf","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2019041206551167200_b22-0701230","volume-title":"Design and analysis of bioavailability and bioequivalence studies","author":"Chow","year":"2000","edition":"2nd ed"},{"key":"2019041206551167200_b23-0701230","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/0091270007307877","article-title":"Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects","volume":"47","author":"Shoaf","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"2019041206551167200_b24-0701230","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2019041206551167200_b25-0701230","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J Pharmacokinet Biopharm"},{"key":"2019041206551167200_b26-0701230","unstructured":"Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products\u2014general considerations. www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070124.pdf (accessed 2012 Oct 31)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/14\/1230\/28364063\/ajhp1230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T16:36:14Z","timestamp":1715618174000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/70\/14\/1230\/5112227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,15]]},"references-count":26,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2013,7,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp120543","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,7,15]]},"published":{"date-parts":[[2013,7,15]]}}}